早发性卵巢功能不全的动物模型构建

doi:10.12280/gjszjk.20200406

摘要/Abstract

摘要：

由于社会角色转变,女性生育延迟现象明显,女性生育力的降低显著早于全身机体的衰老,卵巢储备一般在35岁开始下降。而早发性卵巢功能不全是女性在40岁之前卵巢功能衰退的临床综合征,以月经紊乱伴高促性腺激素及低雌激素为特征,影响女性的身心健康。目前发病机制尚不明确。早发性卵巢功能不全动物模型是研究的基础,不同模型制备特点不尽相同。本文就早发性卵巢功能不全研究中,常见啮齿类动物模型,如免疫反应、放化疗、连续超排卵、D-半乳糖诱导和基因编辑等模型的制备方法、特点及判断标准进行综述,为探索早发性卵巢功能不全的发病机制、开发新的治疗方法提供研究基础。

关键词: 早发性卵巢功能不全, 模型,动物, 化放疗, 基因, 排卵诱导

Abstract:

The childbearing time of woman has been postponed and the willingness decreased, with a large trend. However, female fertility decrease is earlier than the body physiological senescence, and ovarian reserve remarkably declines from the age of 35. Premature ovarian inscufficiency (POI) is a clinical syndrome of decreased ovarian function before the age of 40, which is characterized by menstrual disorder with high gonadotropin and low estrogen level. It is true that POI affects the physical and mental health of women. At present, the mechanism of POI is not clear. The POI animal model is the basis of the research, and the preparation ways of different models are different. This article reviews the preparation methods, characteristics and judgment criteria of common rodent animal models of POI, such as the models of immune, chemoradiotherapy, continuous ovarian stimulation, D-galactose induction and gene editing. These models provide practical tools for researchers to explore the pathogenesis of POI and to develop new therapeutic ways.

Key words: Primary ovarian insufficiency, Model,animal, Chemoradiotherapy, Genes, Ovulation induction

伏玉洁, 孙小燕, 张学红. 早发性卵巢功能不全的动物模型构建[J]. 国际生殖健康/计划生育, 2021, 40(2): 131-136.

FU Yu-jie, SUN Xiao-yan, ZHANG Xue-hong. Animal Model of Premature Ovarian Insufficiency[J]. Journal of International Reproductive Health/Family Planning, 2021, 40(2): 131-136.

参考文献 38

[1]	陈思瑶. 年龄、基础窦卵泡数与超促排卵方案选择的相关性研究[D]. 长春: 吉林大学, 2019.
[2]	Christianson MS, Wodi P, Talaat K, et al. Primary ovarian insufficiency and human papilloma virus vaccines: a review of the current evidence[J]. Am J Obstet Gynecol, 2020,222(3):239-244. doi: 10.1016/j.ajog.2019.08.045. URL pmid: 31479634
[3]	陈子江, 田秦杰, 乔杰, 等. 早发性卵巢功能不全的临床诊疗中国专家共识[J]. 中华妇产科杂志, 2017,52(9):577-581. doi: 10.3760/cma.j.issn.0529-567x.2017.09.001.
[4]	Rossetti R, Ferrari I, Bonomi M, et al. Genetics of primary ovarian insufficiency[J]. Clin Genet, 2017,91(2):183-198. doi: 10.1111/cge.12921. URL pmid: 27861765
[5]	Meczekalski B, Maciejewska-Jeske M, Podfigurna A. Reproduction in premature ovarian insufficiency patients - from latest studies to therapeutic approach[J]. Prz Menopauzalny, 2018,17(3):117-119. doi: 10.5114/pm.2018.78554. URL pmid: 30356967
[6]	Huang B, Qian C, Ding C, et al. Fetal liver mesenchymal stem cells restore ovarian function in premature ovarian insufficiency by targeting MT1[J]. Stem Cell Res Ther, 2019,10(1):362. doi: 10.1186/s13287-019-1490-8. doi: 10.1186/s13287-019-1490-8 URL pmid: 31783916
[7]	Zhang Q, Huang Y, Sun J, et al. Immunomodulatory effect of human amniotic epithelial cells on restoration of ovarian function in mice with autoimmune ovarian disease[J]. Acta Biochim Biophys Sin (Shanghai), 2019,51(8):845-855. doi: 10.1093/abbs/gmz065.
[8]	Sharif K, Watad A, Bridgewood C, et al. Insights into the autoimmune aspect of premature ovarian insufficiency[J]. Best Pract Res Clin Endocrinol Metab, 2019,33(6):101323. doi: 10.1016/j.beem.2019.101323.
[9]	Yin N, Zhao W, Luo Q, et al. Restoring Ovarian Function With Human Placenta-Derived Mesenchymal Stem Cells in Autoimmune-Induced Premature Ovarian Failure Mice Mediated by Treg Cells and Associated Cytokines[J]. Reprod Sci, 2018,25(7):1073-1082. doi: 10.1177/1933719117732156. doi: 10.1177/1933719117732156 URL pmid: 28954601
[10]	Zhang H, Luo Q, Lu X, et al. Effects of hPMSCs on granulosa cell apoptosis and AMH expression and their role in the restoration of ovary function in premature ovarian failure mice[J]. Stem Cell Res Ther, 2018,9(1):20. doi: 10.1186/s13287-017-0745-5. URL pmid: 29386068
[11]	涂晓娟, 刘丹, 王莹, 等. 胸腺切除小鼠自身免疫性卵巢疾病发生发展的时相性变化[J]. 免疫学杂志, 2019,35(9):744-751. doi: 10.13431/j.cnki.immunol.j.20190117.
[12]	Dong Y, Li H, Li Y, et al. The role of regulatory T cells in thymectomy-induced autoimmune ovarian disease[J]. Am J Reprod Immunol, 2017,78(4). doi: 10.1111/aji.12683.
[13]	Ayala C, Celis ME. Experimental autoimmune oophoritis and α-melanocyte-stimulating hormone[J]. Expert Rev Endocrinol Metab, 2010,5(4):539-547. doi: 10.1586/eem.10.11.
[14]	Meirow D, Biederman H, Anderson RA, et al. Toxicity of chemotherapy and radiation on female reproduction[J]. Clin Obstet Gynecol, 2010,53(4):727-739. doi: 10.1097/GRF.0b013e3181f96b54.
[15]	Luan Y, Edmonds ME, Woodruff TK, et al. Inhibitors of apoptosis protect the ovarian reserve from cyclophosphamide[J]. J Endocrinol, 2019,240(2):243-256. doi: 10.1530/JOE-18-0370.
[16]	Sonigo C, Beau I, Grynberg M, et al. AMH prevents primordial ovarian follicle loss and fertility alteration in cyclophosphamide-treated mice[J]. FASEB J, 2019,33(1):1278-1287. doi: 10.1096/fj.201801089R.
[17]	Wu Y, Ma C, Zhao H, et al. Alleviation of endoplasmic reticulum stress protects against cisplatin-induced ovarian damage[J]. Reprod Biol Endocrinol, 2018,16(1):85. doi: 10.1186/s12958-018-0404-4. URL pmid: 30176887
[18]	Jang H, Lee OH, Lee Y, et al. Melatonin prevents cisplatin-induced primordial follicle loss via suppression of PTEN/AKT/FOXO3a pathway activation in the mouse ovary[J]. J Pineal Res, 2016,60(3):336-347. doi: 10.1111/jpi.12316. doi: 10.1111/jpi.12316 URL pmid: 26882203
[19]	Wang Y, Liu M, Johnson SB, et al. Doxorubicin obliterates mouse ovarian reserve through both primordial follicle atresia and overactivation[J]. Toxicol Appl Pharmacol, 2019,381:114714. doi: 10.1016/j.taap.2019.114714.
[20]	Manshadi MD, Navid S, Hoshino Y, et al. The effects of human menstrual blood stem cells-derived granulosa cells on ovarian follicle formation in a rat model of premature ovarian failure[J]. Microsc Res Tech, 2019,82(6):635-642. doi: 10.1002/jemt.23120. doi: 10.1002/jemt.23120 URL pmid: 30582244
[21]	贺宇恒, 谭容容, 浦丹华, 等. 放疗致卵巢早衰小鼠动物模型的构建[J]. 生殖医学杂志, 2017,26(12):1243-1249. doi: 10.3969/j.issn.1004-3845.2017.12.016.
[22]	Wang K, Liu C, Di CJ, et al. Kojic acid protects C57BL/6 mice from gamma-irradiation induced damage[J]. Asian Pac J Cancer Prev, 2014,15(1):291-297. doi: 10.7314/apjcp.2014.15.1.291. doi: 10.7314/apjcp.2014.15.1.291 URL pmid: 24528043
[23]	Zhe J, Chen S, Chen X, et al. A novel heterozygous splice-altering mutation in HFM1 may be a cause of premature ovarian insufficiency[J]. J Ovarian Res, 2019,12(1):61. doi: 10.1186/s13048-019-0537-x. URL pmid: 31279343
[24]	Venturella R, De Vivo V, Carlea A, et al. The Genetics of Non-Syndromic Primary Ovarian Insufficiency: A Systematic Review[J]. Int J Fertil Steril, 2019,13(3):161-168. doi: 10.22074/ijfs.2019.5599.
[25]	Liu MN, Zhang K, Xu TM . The role of BMP15 and GDF9 in the pathogenesis of primary ovarian insufficiency[J]. Hum Fertil (Camb), 2019 Oct 14: 1-8. doi: 10.1080/14647273.2019.1672107.
[26]	Mok-Lin E, Ascano M Jr, Serganov A, et al. Premature recruitment of oocyte pool and increased mTOR activity in Fmr1 knockout mice and reversal of phenotype with rapamycin[J]. Sci Rep, 2018,8(1):588. doi: 10.1038/s41598-017-18598-y. doi: 10.1038/s41598-017-18598-y URL pmid: 29330421
[27]	Ghadami M, El-Demerdash E, Salama SA, et al. Toward gene therapy of premature ovarian failure: intraovarian injection of adenovirus expressing human FSH receptor restores folliculogenesis in FSHR(-/-) FORKO mice[J]. Mol Hum Reprod, 2010,16(4):241-250. doi: 10.1093/molehr/gaq003.
[28]	Yang X, Zhang X, Jiao J, et al. Rare variants in FANCA induce premature ovarian insufficiency[J]. Hum Genet, 2019,138(11/12):1227-1236. doi: 10.1007/s00439-019-02059-9.
[29]	Zhang D, Liu Y, Zhang Z, et al. Basonuclin 1 deficiency is a cause of primary ovarian insufficiency[J]. Hum Mol Genet, 2018,27(21):3787-3800. doi: 10.1093/hmg/ddy261.
[30]	Zhou Y, Qin Y, Qin Y, et al. Wdr62 is involved in female meiotic initiation via activating JNK signaling and associated with POI in humans[J]. PLoS Genet, 2018,14(8):e1007463. doi: 10.1371/journal.pgen.1007463. URL pmid: 30102701
[31]	Miao Y, Wang P, Xie B, et al. BRCA2 deficiency is a potential driver for human primary ovarian insufficiency[J]. Cell Death Dis, 2019,10(7):474. doi: 10.1038/s41419-019-1720-0. URL pmid: 31209201
[32]	Song ZH, Yu HY, Wang P, et al. Germ cell-specific Atg7 knockout results in primary ovarian insufficiency in female mice[J]. Cell Death Dis, 2015,6(1):e1589. doi: 10.1038/cddis.2014.559.
[33]	Tsui V, Crismani W. The Fanconi Anemia Pathway and Fertility[J]. Trends Genet, 2019,35(3):199-214. doi: 10.1016/j.tig.2018.12.007. URL pmid: 30683429
[34]	Nie X, Dai Y, Zheng Y, et al. Establishment of a Mouse Model of Premature Ovarian Failure Using Consecutive Superovulation[J]. Cell Physiol Biochem, 2018,51(5):2341-2358. doi: 10.1159/000495895. doi: 10.1159/000495895 URL pmid: 30537739
[35]	张金金. 洋橄榄叶素和坤泰胶囊对衰老卵巢的功能保护及作用机制研究[D]. 武汉: 华中科技大学, 2017.
[36]	Yan Z, Dai Y, Fu H, et al. Curcumin exerts a protective effect against premature ovarian failure in mice[J]. J Mol Endocrinol, 2018,60(3):261-271. doi: 10.1530/JME-17-0214. URL pmid: 29437881
[37]	刘小虎, 赵志慧, 周玥, 等. SIRT1在人参皂苷Rg(1)延缓D-gal诱导的卵巢早衰小鼠模型卵巢早衰中的作用[J/OL]. 中国中药杂志:1-8. (2020-04-27)[2020-05-21]. https://doi.org/10.19540/j.cnki.cjcmm.20200427.403.
[38]	Xie L, Wu S, Cao D, et al. Huyang yangkun formula protects against 4-Vinylcyclohexene diepoxide-induced premature ovarian insufficiency in rats via the Hippo-JAK2/STAT3 signaling pathway[J]. Biomed Pharmacother, 2019,116:109008. doi: 10.1016/j.biopha.2019.109008. URL pmid: 31152926